Tissue Plasminogen Activator for Intracerebral Hemorrhage

This trial tests a new method of using Tissue Plasminogen Activator (tPA) for individuals with intracerebral hemorrhage. Researchers aim to determine if a continuous flow of tPA into the brain clears blood and improves recovery more effectively than administering tPA every 8 hours or using a standard fluid. Individuals with this type of brain bleed who require an external ventricular drain (EVD) might be suitable candidates for the trial. As a Phase 4 trial, this study involves an FDA-approved treatment and seeks to understand how it can benefit more patients.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that a medication called Tissue Plasminogen Activator (tPA) can sometimes cause bleeding in the brain. In studies with stroke patients, about 8% experienced some type of brain bleeding, and around 3% had fatal bleeding. However, these studies also indicate that most people do not experience serious side effects from tPA. It is important to note that the FDA has already approved tPA for treating strokes, which means it is generally considered safe when used correctly. Always discuss the risks and benefits with a doctor before joining a clinical trial.¹²³⁴⁵

Unlike the standard treatments for intracerebral hemorrhage, which typically focus on managing symptoms and preventing complications, the use of Tissue Plasminogen Activator (tPA) aims to directly dissolve the blood clot in the brain. This approach is exciting because tPA, already known for its clot-busting capabilities in stroke patients, is now being evaluated for its ability to actively reduce the size of brain hemorrhages, potentially improving patient outcomes. Additionally, combining tPA with isotonic solution irrigation could enhance its effectiveness, providing a new avenue for treatment that addresses the underlying hemorrhage more directly than current therapies. Researchers are eager to explore whether this combination can lead to faster recovery and improved neurological function compared to standard care.

This trial will compare Tissue Plasminogen Activator (tPA) with isotonic solution irrigation for intracerebral hemorrhage. Research has shown that tPA can improve recovery in stroke patients, with studies finding a 7.2% higher chance of excellent recovery after 90 days compared to those who do not receive it. However, tPA can also increase the risk of brain bleeding. Despite this risk, many patients find the benefits of tPA for strokes outweigh the risks. This treatment is already used for other types of strokes, and this study aims to determine its effectiveness for brain bleeds. Participants in this trial may receive isotonic solution irrigation alone or combined with tPA infusion.¹⁴⁶⁷⁸